Drug screening and development cascade for Chagas disease: an update of in vitro and in vivo experimental models.
Maria de Nazaré Correia Soeiro, Policarpo Ademar Sales, Valéria Rêgo Alves Pereira, Marcos A. Vannier‐Santos, Silvane Maria Fonseca Murta, Andréa Silvestre de Sousa, Luiz Henrique Conde Sangenis, Alejandro Marcel Hasslocher‐Moreno, Núbia Boechat, Frederico Silva Castelo Branco, Fabíola Holetz, Andréa Rodrigues Ávila, Mirian Cláudia de Souza Pereira
Abstract
Chagas disease is a tropical neglected disease that affects millions of people worldwide, still demanding a more effective and safer therapy, especially in its chronic phase which lacks a treatment that promotes substantial parasitological cure. The technical note of Romanha and collaborators published in 2010 aimed establish a guideline with the set of minimum criteria and decision gates for the development of new agents against Trypanosoma cruzi with the focus on developing new antichagasic drugs. In this sense, the present review aims to update this technical note, bringing the state of the art and new advances on this topic in recent years.